347 related articles for article (PubMed ID: 21665049)
21. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics.
Mwinyi J; Johne A; Bauer S; Roots I; Gerloff T
Clin Pharmacol Ther; 2004 May; 75(5):415-21. PubMed ID: 15116054
[TBL] [Abstract][Full Text] [Related]
22. Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers.
Gregory BJ; Chen SM; Murphy MA; Atchley DH; Kamdem LK
J Clin Pharm Ther; 2017 Oct; 42(5):547-553. PubMed ID: 28868654
[TBL] [Abstract][Full Text] [Related]
23. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.
Katz DA; Carr R; Grimm DR; Xiong H; Holley-Shanks R; Mueller T; Leake B; Wang Q; Han L; Wang PG; Edeki T; Sahelijo L; Doan T; Allen A; Spear BB; Kim RB
Clin Pharmacol Ther; 2006 Mar; 79(3):186-96. PubMed ID: 16513443
[TBL] [Abstract][Full Text] [Related]
24. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
Tan QY; Li HD; Zhu RH; Zhang QZ; Zhang J; Peng WX
Am J Cardiovasc Drugs; 2013 Feb; 13(1):17-25. PubMed ID: 23355361
[TBL] [Abstract][Full Text] [Related]
25. SLCO1B1 polymorphism and oral antidiabetic drugs.
Kalliokoski A; Neuvonen PJ; Niemi M
Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):775-81. PubMed ID: 20406215
[TBL] [Abstract][Full Text] [Related]
26. Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy.
Zhang X; Pu Z; Ge J; Shen J; Yuan X; Xie H
Med Sci Monit; 2015 Feb; 21():563-9. PubMed ID: 25701109
[TBL] [Abstract][Full Text] [Related]
27. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Kalliokoski A; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2008 Nov; 18(11):937-42. PubMed ID: 18854776
[TBL] [Abstract][Full Text] [Related]
28. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.
Niemi M; Pasanen MK; Neuvonen PJ
Pharmacol Rev; 2011 Mar; 63(1):157-81. PubMed ID: 21245207
[TBL] [Abstract][Full Text] [Related]
29. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.
Zhang W; He YJ; Han CT; Liu ZQ; Li Q; Fan L; Tan ZR; Zhang WX; Yu BN; Wang D; Hu DL; Zhou HH
Br J Clin Pharmacol; 2006 Nov; 62(5):567-72. PubMed ID: 16796707
[TBL] [Abstract][Full Text] [Related]
30. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
[TBL] [Abstract][Full Text] [Related]
31. Bioequivalence study of two brands of enalapril tablets after single oral administration to healthy volunteers.
Niopas I; Daftsios AC; Nikolaidis N
Int J Clin Pharmacol Ther; 2003 May; 41(5):226-30. PubMed ID: 12776814
[TBL] [Abstract][Full Text] [Related]
32. SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid.
Tornio A; Vakkilainen J; Neuvonen M; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2015 Aug; 25(8):382-7. PubMed ID: 26020121
[TBL] [Abstract][Full Text] [Related]
33. SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril)-Induced Cough: a Pharmacogenetic Study.
Luo JQ; He FZ; Wang ZM; Sun NL; Wang LY; Tang GF; Liu MZ; Li Q; Chen XP; Liu ZQ; Zhou HH; Zhang W
Sci Rep; 2015 Nov; 5():17253. PubMed ID: 26607661
[TBL] [Abstract][Full Text] [Related]
34. Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin.
Choi CI; Lee YJ; Lee HI; Kim BH; Kim MJ; Jang CG; Bae JW; Lee SY
Xenobiotica; 2012 May; 42(5):496-501. PubMed ID: 22077103
[TBL] [Abstract][Full Text] [Related]
35. Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.
Xiang X; Han Y; Neuvonen M; Pasanen MK; Kalliokoski A; Backman JT; Laitila J; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2009 Jun; 19(6):447-57. PubMed ID: 19387419
[TBL] [Abstract][Full Text] [Related]
36. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.
He YJ; Zhang W; Chen Y; Guo D; Tu JH; Xu LY; Tan ZR; Chen BL; Li Z; Zhou G; Yu BN; Kirchheiner J; Zhou HH
Clin Chim Acta; 2009 Jul; 405(1-2):49-52. PubMed ID: 19374892
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses.
Gardner SY; Atkins CE; Sams RA; Schwabenton AB; Papich MG
J Vet Intern Med; 2004; 18(2):231-7. PubMed ID: 15058776
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.
Nunes T; Rocha JF; Vaz-da-Silva M; Falcão A; Almeida L; Soares-da-Silva P
Clin Ther; 2011 Jun; 33(6):776-91. PubMed ID: 21704242
[TBL] [Abstract][Full Text] [Related]
39. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
Chen L; Jiang X; Huang L; Lan K; Wang H; Hu L; Ren J; Li X; Zou Q
Clin Ther; 2009 Oct; 31(10):2242-8. PubMed ID: 19922895
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers.
Marzo A; Dal Bo L; Mazzucchelli P; Monti NC; Crivelli F; Ismaili S; Giusti A; Uhr MR
Arzneimittelforschung; 2002; 52(4):233-42. PubMed ID: 12040965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
